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Weaning of Immunosuppression in Long-Term Recipients of Living 
Related Renal Transplants: A Preliminary Study 
G.V. Mazariego5, H. Ramos, R. Shapiro, A. Zeevi, J.J. Fung, and T.E. Starzl 
A LTHOUGH renal transplantation continues to be 
associated with increasingly good short- and long-
term graft survival, there remains a need for continued 
chronic immunosuppression and this can lead to significant 
complications. I - 3 This has prompted the evaluation of 
withdrawal or modification of immunosuppression by sev-
eral investigators with varying results.4•5 Emerging data 
proposing dendritic cell migration and repopulation with 
chimerism following solid organ transplantation as the basis 
for graft acceptance have further encouraged evaluation of 
titrated withdrawal of immunosuppression in select groups 
of patients.6 - 8 The finding that donor-specific nonreactivity 
and chimerism occur simultaneously in long-term living 
related kidney recipients9 led us to evaluate withdrawal of 
immunosuppression in these patients. 
MATERIALS AND METHODS 
Eight long-term recipients of continuously functioning living re-
lated renal allografts were weaned from immunosuppression. 
Three patients were noncompliant and had self-weaned their 
medications many years previously. Patient demographic data are 
listed in Table 1. An additional five patients were deliberately 
weaned from their immunosuppression according to the following 
criteria: the patients were recipients of living related kidneys, more 
than 5 years posttransplant, with at least 2 years of stable graft 
function. Baseline renal biopsy without evidence of rejection was 
required, as was a compliant medical history and complications 
related to immunosuppression. 
Immunologic reactivity was assessed when available by in vitro 
mixed lymphocyte reaction (MLR) and cell-mediated Iymphotox-
ICily (CML). Unidirectional human MLR cultures used 5 x 104 
responder and 5 x 104 irradiated stimulator (donor and third 
party) cells in tissue culture media supplemented with human 
serum. The degree of labeled thymidine incorporation during the 
final 20 hours of incubation determined proliferation. 
CML was assessed between recipient lymphocytes and donor 
and third-party targets by using effector lymphocytes incubated 
with Cr-Iabeled target cells at various effector:target ratios. 
Weaning proceeded in the following manner. Mter a baseline 
renal biopsy was obtained. prednisone was weaned to less than 5 
mg/d. The ACfH stimulation test was used to assess for intact 
adrenocortical function. as these patients had been on steroids for 
many years. IO•11 Patients with an appropriate incremental increase 
in cortisol levels following stimulation with ACfH were weaned off 
prednisone completely. 12 The remaining immunosuppressant (aza-
thioprine in all cases except case no. 8) was sequentially reduced by 
50% at monthly intervals. Patient weight, urine output, blood urea 
nitrogen, and serum creatinine were followed on a monthly basis. 
RESULTS 
Baseline immunosuppression, donor relationship, serum 
creatinine before and after withdrawal of immunosuppres-
sion, episodes of rejection, and time off immunosuppression 
are listed in Table 2. 
Renal biopsies obtained on patients 4 to 8 had minimal 
background infiltrate with no evidence of rejection. One 
patient developed mild acute cellular rejection diagnosed 
on biopsy at 5 months postweaning and was treated with 
pulse steroids and a return to baseline therapy. His creati-
nine immediately returned to normal. One patient is still in 
the process of being weaned; to date, her immunosuppres-
sion has been decreased by 75% without any untoward 
effect. Current time off immunosuppression for the remain-
ing six patients ranges from 3 months to 29 years (mean = 
12.4 years). One patient is on maintenance steroids (5 mgld 
prednisone) because of adrenal insufficiency. 
Donor-specific reactivity by MLR in patients 3, 4, and 5 
was unresponsive when initially evaluated for weaning of 
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Table 1. Patient Demographic Data 
Patient No. Age Sex Ox 
1. KP 52 M Chronic glomerulonephritis (GN) 
2.5M 45 F Chronic GN 
3. IN 62 M Chronic GN 
4.JW 49 M Chronic GN 
5. OS 45 F Pyelonephritis 
6. LN 52 M Chronic GN 
7.55 37 F Pyelonephritis 
8 .• IK 50 M Renal agenesis 
-SCCalDJD hIP. squamous cell cancer/degenerative joint disease of hip. 
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Date of 
LRRT 
219/63 
2117/64 
1/15164 
7/10/64 
7/19/62 
7/29/66 
5/10n8 
2/25/87 
Complications Related to 
Immunosuppression 
SCCalDJD hip 
Verrucous warts 
Obesity, hypertension. verrucous warts 
HypertenSion. verrucous warts 
Basal celi carcinoma. verrucous warts 
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Table 2. E1fect of Weaning Immunosuppression on Renal Function 
Baseline 
Immunosuppression 
Patient No. (mgld) Great. Pre/Post 
1 Azathioprine (AZA) 0.7/0.9 
2 Pred 15 AZA 25 1.0/1.1 
3 AZA 0.8/0.9 
4 AZA 125/pred 10 1.6/1. 
5 AZA 75 0.8/0.7 
6 AZA 100/pred 10 0.9/0.9 
7 AZA 75/pred 10 1.411.0 
8 AZA5 1.0/3.4-1.2 
7.5 pred 
<CyA 50 
"Maintenance steroids 5/d prednisone (pred) for adrenal cortical insufficiency. 
immunosuppression. Repeat MLR in patients 4 and 5 now 
show a significant response (Fig 1). These patients have 
remained off immunosuppression for 1 and 2 years, respec-
tively, and have normal serum creatinines. The MLR of 
patient 3 would be expected to remain unresponsive, as he 
is a double haplotype match. CML activity remains absent 
in patients 3, 4, and 5 (Table 3). 
Skin lesions were a prominent complication in these 
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Fig 1. Effect of weaning immunosuppression on donor-specific 
MLR. T. P. = third party cells. 
Rejection Time Off Drug (y) 
No 29 
No 148 
No 28 
No 2 
No 
No Still weaning; doses decreased by 
75% 
No 3 months 
Yes 5 months (then restarted) 
long-term recipients. One patient had metastatic squamous 
cell cancer. Four others had disfiguring verrucous warts. 
Patients 4 to 7 have had dramatic improvement of their 
verrucous lesions. Patient 4 had successful surgical therapy 
for his metastatic squamous cell lesion. 
DISCUSSION 
Long-term survival following renal transplantation has been 
previously reported. 13 Multiple drug immunosuppressive 
therapy based on steroids and azathioprine was found to 
prevent or treat renal allograft rejection in the early clinical 
experience. 14.IS The addition of cyclosporine (CyA) to the 
immunosuppressive regimen significantly improved graft 
survival. 16 
The risks of chronic immunosuppression have been well 
described,17 and include opportunistic infection and neo-
plasia. 18•19 Less life-threatening but equally disabling se-
quelae of immunosuppression such as steroid-related 
weight gain, edema, growth retardation, and osteopenia 
have also had significant morbidity.10 CyA-related nephro-
toxicity and hypertension have also been described exten-
sively.17 
The benefits of withdrawal of immunosuppression21.22 
must be weighed against the dangers of graft rejection and 
loss. Our data suggest that weaning of immunosuppression 
can be carried out in a select group of patients. Only one 
patient has demonstrated rejection during weaning of im-
munosuppression. Absolute or relative donor-specific unre-
sponsiveness with MLR prior to weaning was shown in 
three patients available for study who maintained normal 
renal function after weaning. Patients 4 and 5 have had 
return of antidonor reactivity on MLR but not CML; 
clinically, they have had no evidence of rejection. The 
recovery of MLR in the absence of cytotoxic effector cells is 
under investigation. 
The study remains preliminary and the enrolled patient 
number is small. It is known that serum creatinine is not 
completely accurate as an assessment of renal function. 
Studies using creatinine clearance or glomerular filtration 
will be more conclusive. We continue to follow up these 
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Table 3. MLR and CML Data 
Patient No. Donor Haplotype Match MLR CML 
1 Fraternal twin Double Not available (N/A) NlA 
2 Father Single NlA 
3 Sister Double Unresponsive 
4 Aunt No haplotype; one class II match Unresponsive -+ responsive 
N/A 
Nonresponsive 
Nonresponsive 
Nonresponsive 
N/A 
5 Mother Single 
6 Brother Single 
7 Brother Single 
8 Sister Single 
patients as well as consider additional suitable patients for 
withdrawal of immunosuppression. 
CONCLUSION 
How to safely wean immunosuppression in kidney recipi-
ents is still unknown. The kidney is known to be susceptible 
to rapid rejection from preformed antibodies. whereas the 
liver. for example. has been said to be tolerogenic.23 We 
have postulated that the critical difference may be the 
leukocyte component of the organ, thus explaining why the 
leukocyte-poor kidney is less likely to be tolerogenic. Thus, 
weaning is expected to be more dangerous for kidney than 
for liver recipients and should not be recommended except 
for disabling or life-threatening indications. Therapies to 
augment cell migration with infusion of donor bone marrow 
at the time of solid organ transplantation are a strategy to 
balance cell traffic in the direction of graft acceptance,24 
and these are expected to increase the eventual possibility 
of achieving a drug-free state. CyA may be safely withdrawn 
from recipients of HLA identical living related grafts after 
a year of stable graft function,S yet others report lack of 
predictive immunologic parameters in this same "good 
risk" category of patients.2S Our data suggest that some 
recipients of living related HLA nonidentical grafts may be 
able to discontinue immunosuppression. The clinical "tol-
erance" exhibited here may be explained by the leukocyte 
microchimerism previously demonstrated. An attempt at 
complete weaning may be indicated in long-term survivors 
of living related kidney grafts, especially in those with 
significant complications, but close monitoring of renal 
function is required and long-term results are unknown. 
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